Australia's most trusted
source of pharma news
Wednesday, 29 April 2026
Posted 29 April 2026 PM
The time between TGA approval of a medicine and PBS listing has dropped just 1.9 per cent to an average of 712 days but “that’s nearly two years – time many patients simply don’t have,” Amgen’s ANZ General Manager, Keith Jones, said.
In its ninth edition Amgen’s Australian Patient Access Gap Tracker reinforces that innovative medical breakthroughs mean little if patients can’t equitably access them.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.